2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,98%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
1 t sittenEveryone who has invested in this garbage firm has lost their money, including me. There is no hope or future. It’s just about reducing your loss as much as possible, and selling as soon as possible
- ·2 t sittenJust try to watch this video 5:30 min into the video, and it doesn't look good if it's true? https://www.youtube.com/watch?v=sGBpL3-P--ABut just look at how it has gone with solar cells, batteries and maybe soon the car industry
1 t sittenTämä julkaisu on poistettu.
- ·3 t sittenClosing price US: 298.3.. Closes at the highest US price, which is very positive for tomorrow's opening. There was a fight for the last shares in the last 5 minutes before closing. This was hit by algorithms and subsequent herd selling on Tuesday evening. The fact that it recovered so much today, sniffing at 302 and closing at 298, which is 3% up in the US, tells a lot. I foresee 330 in 4-6 weeks when sales have started in Germany and Novo has identified launches in other selected EU countries. The turnaround in the financial statements for the first 6 months is simply impressive, so will the last half of the year actually turn 2026 into marginally positive growth? .. I'm actually starting to believe it and I think the market is also considering the idea.330 I also see coming back quickly, 400 is a bit further away and depends heavily on the pill's success and distribution.
·4 t sitten · MuokattuWhen one isolates Novo Nordisk and removes Eli Lilly from the equation, it is clear that Novo Nordisk is a historically strong and extremely profitable business in itself. Hooray for that. Okay, Eli Lilly is king, there's no doubt about that, but by God, I'm tired of the constant comparison. Wish investors didn't constantly compare percentages of weight loss and the resulting constant price fluctuations. How nice it would be if the price increase could resemble a global index fund. Ultra small increase every day with small setbacks. Then all those who make a quick buck by constantly buying and selling would disappear and we long-term investors would rejoice every day that we beat inflation and get a little richer every day. I know the world isn't like that, but I think my temperament would suit it better. It was a fun fix at the start, but now 2 years have passed and we've gotten nowhere. And yes, now you'll write that I'm investing in the wrong thing - but I also have global funds and Coca Cola :-)
If you take Novo's total profit over the last 10 years, it is over 40% higher than Eli Lilly. The largest earnings are in the American market, and Eli Lilly's products are newer than Novo's and are therefore not under such high price pressure. Everyone has written off CagriSema even though Novo is only a few percentage points behind in weight loss when comparing an approved product Zepbound with a product under development CagriSema. Everyone also wrote off the Wegovy pill last year, but it has clearly won over flopdayo. I believe the same can happen for CagriSema, which has been written off but will sell much more than expected. Novo's insulin products have won, among other things, because they have fewer side effects than competitors. If you look at this link below, Eli Lilly's TIRZEPATIDE (Mounjaro) has far more side effects than Semaglutide. CagriSema cannot be measured solely by weight loss, but side effects are more important for many patients. Let's see. It's too early to write off Novo as the loser of the weight loss market. https://www.independent.co.uk/news/uk/home-news/weight-loss-drug-deaths-side-effects-wegovy-mounjaro-b3028674.html?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,98%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 t sittenEveryone who has invested in this garbage firm has lost their money, including me. There is no hope or future. It’s just about reducing your loss as much as possible, and selling as soon as possible
- ·2 t sittenJust try to watch this video 5:30 min into the video, and it doesn't look good if it's true? https://www.youtube.com/watch?v=sGBpL3-P--ABut just look at how it has gone with solar cells, batteries and maybe soon the car industry
- 1 t sittenTämä julkaisu on poistettu.
- ·3 t sittenClosing price US: 298.3.. Closes at the highest US price, which is very positive for tomorrow's opening. There was a fight for the last shares in the last 5 minutes before closing. This was hit by algorithms and subsequent herd selling on Tuesday evening. The fact that it recovered so much today, sniffing at 302 and closing at 298, which is 3% up in the US, tells a lot. I foresee 330 in 4-6 weeks when sales have started in Germany and Novo has identified launches in other selected EU countries. The turnaround in the financial statements for the first 6 months is simply impressive, so will the last half of the year actually turn 2026 into marginally positive growth? .. I'm actually starting to believe it and I think the market is also considering the idea.330 I also see coming back quickly, 400 is a bit further away and depends heavily on the pill's success and distribution.
- ·4 t sitten · MuokattuWhen one isolates Novo Nordisk and removes Eli Lilly from the equation, it is clear that Novo Nordisk is a historically strong and extremely profitable business in itself. Hooray for that. Okay, Eli Lilly is king, there's no doubt about that, but by God, I'm tired of the constant comparison. Wish investors didn't constantly compare percentages of weight loss and the resulting constant price fluctuations. How nice it would be if the price increase could resemble a global index fund. Ultra small increase every day with small setbacks. Then all those who make a quick buck by constantly buying and selling would disappear and we long-term investors would rejoice every day that we beat inflation and get a little richer every day. I know the world isn't like that, but I think my temperament would suit it better. It was a fun fix at the start, but now 2 years have passed and we've gotten nowhere. And yes, now you'll write that I'm investing in the wrong thing - but I also have global funds and Coca Cola :-)If you take Novo's total profit over the last 10 years, it is over 40% higher than Eli Lilly. The largest earnings are in the American market, and Eli Lilly's products are newer than Novo's and are therefore not under such high price pressure. Everyone has written off CagriSema even though Novo is only a few percentage points behind in weight loss when comparing an approved product Zepbound with a product under development CagriSema. Everyone also wrote off the Wegovy pill last year, but it has clearly won over flopdayo. I believe the same can happen for CagriSema, which has been written off but will sell much more than expected. Novo's insulin products have won, among other things, because they have fewer side effects than competitors. If you look at this link below, Eli Lilly's TIRZEPATIDE (Mounjaro) has far more side effects than Semaglutide. CagriSema cannot be measured solely by weight loss, but side effects are more important for many patients. Let's see. It's too early to write off Novo as the loser of the weight loss market. https://www.independent.co.uk/news/uk/home-news/weight-loss-drug-deaths-side-effects-wegovy-mounjaro-b3028674.html?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Irtoamispäivä 14.8.
3,98%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 t sittenEveryone who has invested in this garbage firm has lost their money, including me. There is no hope or future. It’s just about reducing your loss as much as possible, and selling as soon as possible
- ·2 t sittenJust try to watch this video 5:30 min into the video, and it doesn't look good if it's true? https://www.youtube.com/watch?v=sGBpL3-P--ABut just look at how it has gone with solar cells, batteries and maybe soon the car industry
- 1 t sittenTämä julkaisu on poistettu.
- ·3 t sittenClosing price US: 298.3.. Closes at the highest US price, which is very positive for tomorrow's opening. There was a fight for the last shares in the last 5 minutes before closing. This was hit by algorithms and subsequent herd selling on Tuesday evening. The fact that it recovered so much today, sniffing at 302 and closing at 298, which is 3% up in the US, tells a lot. I foresee 330 in 4-6 weeks when sales have started in Germany and Novo has identified launches in other selected EU countries. The turnaround in the financial statements for the first 6 months is simply impressive, so will the last half of the year actually turn 2026 into marginally positive growth? .. I'm actually starting to believe it and I think the market is also considering the idea.330 I also see coming back quickly, 400 is a bit further away and depends heavily on the pill's success and distribution.
- ·4 t sitten · MuokattuWhen one isolates Novo Nordisk and removes Eli Lilly from the equation, it is clear that Novo Nordisk is a historically strong and extremely profitable business in itself. Hooray for that. Okay, Eli Lilly is king, there's no doubt about that, but by God, I'm tired of the constant comparison. Wish investors didn't constantly compare percentages of weight loss and the resulting constant price fluctuations. How nice it would be if the price increase could resemble a global index fund. Ultra small increase every day with small setbacks. Then all those who make a quick buck by constantly buying and selling would disappear and we long-term investors would rejoice every day that we beat inflation and get a little richer every day. I know the world isn't like that, but I think my temperament would suit it better. It was a fun fix at the start, but now 2 years have passed and we've gotten nowhere. And yes, now you'll write that I'm investing in the wrong thing - but I also have global funds and Coca Cola :-)If you take Novo's total profit over the last 10 years, it is over 40% higher than Eli Lilly. The largest earnings are in the American market, and Eli Lilly's products are newer than Novo's and are therefore not under such high price pressure. Everyone has written off CagriSema even though Novo is only a few percentage points behind in weight loss when comparing an approved product Zepbound with a product under development CagriSema. Everyone also wrote off the Wegovy pill last year, but it has clearly won over flopdayo. I believe the same can happen for CagriSema, which has been written off but will sell much more than expected. Novo's insulin products have won, among other things, because they have fewer side effects than competitors. If you look at this link below, Eli Lilly's TIRZEPATIDE (Mounjaro) has far more side effects than Semaglutide. CagriSema cannot be measured solely by weight loss, but side effects are more important for many patients. Let's see. It's too early to write off Novo as the loser of the weight loss market. https://www.independent.co.uk/news/uk/home-news/weight-loss-drug-deaths-side-effects-wegovy-mounjaro-b3028674.html?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt